Date: 17-20 April 2018
Venue: Edinburgh International Conference Centre, UK
HIV Oral Research Presentations: Session 5
Abstract O34: HIV-2 in the United Kingdom – management and antiretroviral treatment outcomes
Dr Penelope Sellers, Barts Health NHS Trust, London
Abstract O35: Safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected adults on chronic haemodialysis
Mr Richie Castles, Gilead Sciences Ltd
Abstract O36: Plasma NRTI concentrations and renal function in people with HIV
Dr Xinzhu Wang, Imperial College London
Abstract O37: Renal, inflammatory and bone biomarkers following switch to the DTG + RPV 2-drug Regimen: the SWORD-1 and SWORD-2 Studies
Professor Chloe Orkin, Barts Health NHS Trust, London
Abstract O38: Platelet function upon switching to tenofovir alafenamide (TAF) verses continuing abacavir (ABC): A randomised substudy
Dr Patrick Mallon, University College Dublin
Abstract O39: 5-and10-year survival in a large cohort of patients with HIV associated non-cirrhotic portal hypertension (NCPH)
Dr Kate Childs, King's College Hospital, London
Click here to go back to all presentations.